Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Optimization Achieved 78% year-over-year revenue growth driven by MyPlifer's U.S. launch and robust global Expanded Access Program (EAP) reimbursements. Optimized the corporate portfolio by divesting non-core SDX assets for $50 million, allowing management to focus exclusively on high-impact rare disease treatments. Successfully reached approximately 50% of the diagnosed U.S. Niemann-Pick disease type C ...